Cerebellar tDCS in Children With Autism Spectrum Disorder
ConditionAutism Spectrum Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age4-17
SponsorUniversity of Texas Southwestern Medical Center
About this trial
The purpose of this research study is to investigate whether tDCS to the cerebellum (specifically, the right crus I/II area of the cerebellum) of children and young adults with autism spectrum disorders (ASD) is safe and to examine its effects on some of the symptoms of ASD, such as repetitive behaviors and hyperactivity.
Eligibility criteria
Qualifiers
4-17 years old
Diagnosed with ASD and ADOS-2
IQ Score no less than 70 (1.5 Standard Deviations below the mean)
Language Level (Speech consists of, at minimum, flexible, spontaneous, simple, sentences)
Disqualifiers
Brain implants, metal implants, pacemakers, or biomedical devices
Diagnosis of epilepsy
Hearing or visual impairments
History of brain injury
Trial design
Treatments tested in this trial
- tDCS
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
United States Department of Defense
Collaborator
Source ClinicalTrials.gov